The Cooper Companies Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong revenue and earnings growth, driven by product launches, operational efficiencies, and robust cash flow. Guidance for earnings and free cash flow was raised, with continued momentum expected in the Americas and EMEA, while Asia Pac is set to recover in the second half.
-
Operating in growing contact lens and fertility markets, the company is focused on organic growth, product innovation, and capital efficiency. Strategic review is underway to assess business structure, with strong free cash flow and market share gains expected.
Fiscal Year 2025
-
Q4 revenue hit a record $1.065B, up 4.6% year-over-year, with strong MyDay and MiSight growth offsetting softness in China. Fiscal 2026 guidance calls for 4.5–5.5% organic growth and $575–$625M free cash flow, with continued focus on share repurchases and a formal strategic review underway.
-
Organic growth lagged due to clariti inventory drawdown and China e-commerce headwinds, but MyDay and MiSight products are driving recovery. Market share is expected to rebound as MyDay supply improves and private label deals expand. Free cash flow and profitability are set to rise, with a focus on efficiency and shareholder returns.
-
Q3 saw 5.7% revenue growth and strong margins, led by MyDay lens momentum and robust free cash flow, though clariti and Asia-Pacific e-commerce softness weighed on results. Guidance calls for 2%-4% organic growth in Q4, with new MyDay contracts and efficiency initiatives expected to drive 2026 gains.
-
Global medical device operations are driving above-market growth in contact lenses and women's health, with robust innovation in myopia control and premium lens offerings. Operational investments are now yielding margin and free cash flow gains, with further expansion expected as CapEx declines and new products launch.
-
Q2 saw 7% organic revenue growth, margin expansion, and double-digit non-GAAP EPS growth, driven by strong performance in daily silicone hydrogel lenses and surgical products. Guidance was raised for revenue and EPS, but market growth expectations were lowered due to channel inventory and fertility softness.
-
Q1 delivered record revenues and margin expansion, with strong performance in CooperVision and CooperSurgical. Guidance for FY25 remains robust, with EPS raised and free cash flow prioritized for debt reduction. China remains a challenge, but product launches and operational execution are driving growth.
-
Strong growth in both contact lens and fertility businesses is driven by innovation, market leadership, and rising global demand for myopia management and fertility solutions. Investments in manufacturing and technology are improving margins and free cash flow, with no major new investment cycle expected.
Fiscal Year 2024
-
Record annual and Q4 revenues were achieved, with strong growth in both Vision and Surgical segments. Fiscal 2025 guidance calls for 6%–8% organic revenue growth, margin expansion, and continued investment in capacity and innovation, despite currency and competitive headwinds.
-
Strong growth in both vision and surgical segments is driven by macro trends, premium product demand, and innovation in myopia control and fertility. Capacity expansion and operational efficiency are key focuses, with free cash flow improvement targeted for 2026.
-
Strong Q3 results were driven by double-digit growth in contact lens and fertility businesses, with robust market demand and improving margins. Fiscal 2025 guidance anticipates continued 6-8% organic growth, margin expansion, and lower interest expense, supported by product innovation and operational leverage.
-
Achieved record $1B+ revenue quarter with 8% organic growth, double-digit EPS increase, and margin expansion. Both contact lens and fertility businesses posted strong results, with guidance raised for FY24 and positive outlook for FY25.
-
Strong first half growth in contact lenses is driven by rapid capacity expansion and premium product demand, with guidance raised for the second half. Capacity constraints and elevated CapEx are expected to persist, while operational efficiencies and pricing power support margin improvement.
-
The company highlighted strong, consistent growth in both its vision and surgical businesses, with recent investments now driving improved margins and leverage. Vision is benefiting from premium product demand and market share gains, while surgical is rebounding after a systems upgrade. Guidance remains positive, with a focus on long-term growth and operational efficiency.